Cargando…
Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice
Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied the therapeutic potency and escape pathways of bnAb PGDM1400 during monovalent therapy in human i...
Autores principales: | van der Velden, Yme U., Villaudy, Julien, Siteur - van Rijnstra, Esther, van der Linden, Cynthia A., Vink, Monique A., Schermer, Edith E., Weijer, Kees, Berkhout, Ben, Sanders, Rogier W., van Gils, Marit J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755169/ https://www.ncbi.nlm.nih.gov/pubmed/33218286 http://dx.doi.org/10.1080/19420862.2020.1845908 |
Ejemplares similares
-
Early Effects of HTLV-1 Infection on the Activation, Exhaustion, and Differentiation of T-Cells in Humanized NSG Mice
por: Espíndola, Otávio de Melo, et al.
Publicado: (2021) -
A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike
por: van der Velden, Yme U., et al.
Publicado: (2022) -
Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS
por: Wesley, Martina S., et al.
Publicado: (2021) -
ABX464: a good drug candidate instead of a magic bullet
por: Berkhout, Ben, et al.
Publicado: (2015) -
Engineered miniature H1 promoters with dedicated RNA polymerase II or III activity
por: Gao, Zongliang, et al.
Publicado: (2020)